Particle Engineering to Optimise the Performance of Inhaled Therapeutics
The Crystec mSAS® (modified supercritical anti-solvent) process offers distinct advantages in the development of high-performing inhaled products.
Particle Engineering to Optimise the Performance of Inhaled Therapeutics Read More »